Article | Published:

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

Nature Medicine volume 13, pages 828835 (2007) | Download Citation

Abstract

Antigen-specific CD8+ T-cell tolerance, induced by myeloid-derived suppressor cells (MDSCs), is one of the main mechanisms of tumor escape. Using in vivo models, we show here that MDSCs directly disrupt the binding of specific peptide–major histocompatibility complex (pMHC) dimers to CD8-expressing T cells through nitration of tyrosines in a T-cell receptor (TCR)-CD8 complex. This process makes CD8-expressing T cells unable to bind pMHC and to respond to the specific peptide, although they retain their ability to respond to nonspecific stimulation. Nitration of TCR-CD8 is induced by MDSCs through hyperproduction of reactive oxygen species and peroxynitrite during direct cell-cell contact. Molecular modeling suggests specific sites of nitration that might affect the conformational flexibility of TCR-CD8 and its interaction with pMHC. These data identify a previously unknown mechanism of T-cell tolerance in cancer that is also pertinent to many pathological conditions associated with accumulation of MDSCs.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807–839 (2003).

  2. 2.

    et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5, 780–787 (1999).

  3. 3.

    et al. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63, 9007–9015 (2003).

  4. 4.

    , & Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 175, 4583–4592 (2005).

  5. 5.

    et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123–1131 (2006).

  6. 6.

    , & Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53–65 (2006).

  7. 7.

    The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941–952 (2004).

  8. 8.

    & Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55, 237–245 (2006).

  9. 9.

    , , & Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol. Immunother. 54, 1137–1142 (2005).

  10. 10.

    et al. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J. Immunol. 166, 678–689 (2001).

  11. 11.

    & Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61, 4756–4760 (2001).

  12. 12.

    et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044–3048 (2005).

  13. 13.

    , , , & Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics. J. Mol. Med. 78, 673–683 (2001).

  14. 14.

    & Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351–358 (2002).

  15. 15.

    & Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 74, 186–196 (2003).

  16. 16.

    , , , & A cytotoxic T lymphocyte clone can recognize the same naturally occurring self peptide in association with a self and nonself class I MHC protein. Mol. Immunol. 31, 967–975 (1994).

  17. 17.

    , , , & Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol. 157, 670–678 (1996).

  18. 18.

    The neutrophils respiratory burst oxidase. in The Neutrophils. New Outlook for Old Cells (ed. Gabrilovich, D.I.) 35–85 (Imperial College Press, London, 2005).

  19. 19.

    & The formation of peroxynitrite in vivo from nitric oxide and superoxide. Chem. Biol. Interact. 96, 203–206 (1995).

  20. 20.

    , , & Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989–999 (2004).

  21. 21.

    & Quantification of total oxidant scavenging capacity of antioxidants for peroxynitrite, peroxyl radicals, and hydroxyl radicals. Toxicol. Appl. Pharmacol. 156, 96–105 (1999).

  22. 22.

    & Peroxynitrite scavenging by different antioxidants. Part I: convenient assay. Nitric Oxide 3, 40–54 (1999).

  23. 23.

    et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to the interferon-γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193, 661–670 (2000).

  24. 24.

    & STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174, 4880–4891 (2005).

  25. 25.

    et al. Oxidation, tyrosine nitration and cytostasis induction in the absence of inducible nitric oxide synthase. Int. J. Mol. Med. 1, 787–795 (1998).

  26. 26.

    , & Selective nitration of histone tyrosine residues in vivo in mutatect tumors. J. Biol. Chem. 277, 3614–3621 (2002).

  27. 27.

    , , , & Crystal structure of nitrated human manganese superoxide dismutase: mechanism of inactivation. Free Radic. Biol. Med. 40, 453–458 (2006).

  28. 28.

    , , & Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br. J. Clin. Pharmacol. 53, 189–192 (2002).

  29. 29.

    et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther. 9, 345–352 (2002).

  30. 30.

    , , , & CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann. Otol. Rhinol. Laryngol. 109, 749–754 (2000).

  31. 31.

    , , & Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24, 431–446 (2001).

  32. 32.

    , , & Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138–2145 (2003).

  33. 33.

    , , , & CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J. Immunol. 176, 2085–2094 (2006).

  34. 34.

    et al. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J. Immunol. 169, 3180–3190 (2002).

  35. 35.

    , , & A shistosome expressed immunomodulatory glycoconjugate expand peritoneal Gr1+ macrophages that suppress naive CD4+ T cell proliferation via an interferon-γ and nitric oxide dependent mechanism. J. Immunol. 167, 4293–4302 (2001).

  36. 36.

    , , & Increased TCR avidity after T cell activation: a mechanism for sensing low-density antigen. Immunity 14, 135–143 (2001).

  37. 37.

    et al. Peripheral “CD8 tuning” dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J. Immunol. 174, 619–627 (2005).

  38. 38.

    , , & Transient loss of MHC class I tetramer binding after CD8+ T cell activation reflects altered T cell effector function. J. Immunol. 175, 1507–1515 (2005).

  39. 39.

    & Peroxynitrite reactivity with amino acids and proteins. Amino Acids 25, 295–311 (2003).

  40. 40.

    et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. USA 102, 4185–4190 (2005).

  41. 41.

    et al. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335, 271–274 (1988).

  42. 42.

    et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63, 4441–4449 (2003).

  43. 43.

    , , & Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166, 5398–5406 (2001).

Download references

Acknowledgements

We thank S. Kusmartsev for assistance at the beginning of this project and J. DeComarmond for technical assistance with manuscript preparation. This work was supported by the National Institutes of Health (grant RO1CA 84488 to D.I.G.) and, in part, by the Analytic Microscopy and Flow Cytometry Core Facility at the H. Lee Moffitt Cancer Center.

Author information

Affiliations

  1. H. Lee Moffitt Cancer Center, University of South Florida, 12902 Magnolia Drive, Tampa, Florida 33647, USA.

    • Srinivas Nagaraj
    • , Loveleen Kang
    • , Donna L Herber
    •  & Dmitry I Gabrilovich
  2. John Hopkins University Medical School, 720 Rutland Avenue, Baltimore, Maryland 21205, USA.

    • Kapil Gupta
    •  & Jonathan Schneck
  3. University of Nebraska Medical Center and Eppley Cancer Center, 986805 Nebraska Medical Center, Omaha, Nebraska 68198, USA.

    • Vladimir Pisarev
    • , Leo Kinarsky
    •  & Simon Sherman

Authors

  1. Search for Srinivas Nagaraj in:

  2. Search for Kapil Gupta in:

  3. Search for Vladimir Pisarev in:

  4. Search for Leo Kinarsky in:

  5. Search for Simon Sherman in:

  6. Search for Loveleen Kang in:

  7. Search for Donna L Herber in:

  8. Search for Jonathan Schneck in:

  9. Search for Dmitry I Gabrilovich in:

Contributions

S.N. performed most of the experiments, analyzed data and wrote the manuscript; K.G. performed some of binding experiments; V.P. contributed to overall research design and molecular modeling analysis; L.K. performed molecular modeling analysis; S.S. performed molecular modeling analysis; L.K. performed immunohistology in human tissues; D.H. performed immunohistology in mouse tissues; J.S. contributed to overall research design and analysis; D.I.G. designed the experiments, analyzed the data, wrote the manuscript and supervised the project.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Dmitry I Gabrilovich.

Supplementary information

PDF files

  1. 1.

    Supplementary Fig. 1

    Experimental model of MDSC-induced T-cell tolerance.

  2. 2.

    Supplementary Fig. 2

    MSDC disrupt binding of pMHC to to CD8+ T cells in 2C models.

  3. 3.

    Supplementary Fig. 3

    Positioning of the potential sites of a TCR/pMHC/CD8 nitration.

  4. 4.

    Supplementary Fig. 4

    Effect of nitration of tyrosines in TCR and CD8 molecules.

  5. 5.

    Supplementary Fig. 5

    Nitrotyrosine positive CD8+ T cells in lymphoid tissues.

  6. 6.

    Supplementary Fig. 6

    Duration of CD8+ T-cell tolerance induced by MDSC.

  7. 7.

    Supplementary Fig. 7

    Myeloid derived suppressor cells associate with T cells.

  8. 8.

    Supplementary Fig. 8

    Effect of uric acid on T-cell activation in vivo.

  9. 9.

    Supplementary Discussion

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm1609

Further reading